drugset / Trial / NCT05890638

Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT05890638

Phase 3 Unknown 74 enrolled Neutec Ar-Ge San ve Tic A.Ş
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to compare the acute bronchodilator effect of the Ipratropium / Levosalbutamol 1.25 mg \& 0.5 mg / 2.5 mL fixed dose combination nebuliser solution or Levosalbutamol 1.25 mg / 3 mL nebuliser solution and Ipratropium 500 mcg nebuliser solution in stable moderate-severe-very severe COPD patients.

Timeline

Start
2023-08-25
Primary completion
2024-02-06
Completion
2024-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipratropium Small molecule 500 ug Inhaled
Subject Ipratropium Small molecule 1.25 mg Inhaled
Subject Levalbuterol Other / unclassified 0.5 mg Inhaled
Subject Levalbuterol Other / unclassified 1.25 mg Inhaled